Oral IL-23 Receptor Antagonist Peptide Shows Promising Results for Plaque Psoriasis 

JNJ-77242113 has been evaluated for its efficacy in the treatment of moderate-to-severe plaque psoriasis. An IL-23-receptor antagonist peptide, it selectively blocks interleukin-23 signaling and downstream cytokine production and can be administered orally.

During a phase 2 dose-finding trial, investigators randomly assigned patients to receive JNJ-77242113 at a dose of 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, or 100 mg twice daily or placebo for a period of 16 weeks.

A total of 255 patients were selected for randomization. The primary end point of the study was a reduction from baseline of at least 75% in the Psoriasis Area and Severity Index (PASI) score at week 16.

Results of the study demonstrated that at week 16, a higher percentage of patients in the JNJ-77242113 groups saw PASI 75 than those in placebo group, with researchers noting a significant dose-response relationship.

  • 37% from the 25 mg once daily group
  • 51% from the 25 mg twice daily group
  • 58% from the 50 mg once daily group
  • 65% from the 100 mg once daily group
  • 79% from the 100 mg twice daily group

The most common adverse events reported during the study included coronavirus disease 2019 and nasopharyngitis.


Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.